Important LymPro Distinction: Univariant Versus Mu
Post# of 30028
Posted On: 08/27/2014 12:51:34 PM
Important LymPro Distinction: Univariant Versus Multivariant!
Did you know that Eli Lilly's Amivid, our current competition, only tests for one variable or biomarker? ( Univariant) LymPro tests for 5 univariants. Some of these univariant numbers reported on last month were only in the 70s and 80s. Uninformed shareholders, including me, were disappointed by these numbers. We were expecting numbers in the 90s. What I didn't understand before was that we can report on each univariant biomarker independently. When we do.... we get a lesser number than when we combine all five together (multivariant). It is when we combine all of them together that we get the good high results in the 90s.
We all need to get more informed about this stuff. It can be confusing. AMBS might release numbers that horrifies shareholders, but thrills scientists! That means we're not up to speed. I am not a scientist, and I welcome more qualified science people to explain this better than I'm attempting to. But my understanding is that if you only take a reading on just one of our univariant biomarkers, the numbers are going to be much lower than what we've been accustomed to talking about on the mb. It's when you compile all of them together that we get the nice multivariant numbers that put us above our competition.
Not only will LymPro be more accurate than Amivid, but LymPro is less invasive than amivid. A big MRI-like machine is needed to detect a solution that they shoot into our veins and goes into our head. And it costs around $3,500 for the test. LymPro will cost between $1,000 and $1,500, initially. LymPro is less expensive, less invasive, and more accurate. Big Pharma doing AD clinical trials will be waiting for LymPro big time!!
Another distinction we need to make when given LymPro numbers is if they are comparing Alzheimer's patients with Healthy People, or whether they're being compared to people with other forms of dementia. The numbers are different and yet we never make these distinctions in our mb discussions.
We can't just rely on our favorite metric of spec & sens numbers in the 90s without making these important distinctions about the data being presented. The sens & spec 90s numbers is a convenient way for non-science people who are here primarily for the investment to talk about messy science stuff....but unless we want another 45% haircut in the future when Lympro data is being presented, we need to raise the level of science in our mb discussions. We need this because shareholders react after data releases in very emotional ways....fueled by message board comments from flippers with dishonest, greedy motives to profit off our ignorance.
Data is coming and we need to be prepared to understand it better!
Did you know that Eli Lilly's Amivid, our current competition, only tests for one variable or biomarker? ( Univariant) LymPro tests for 5 univariants. Some of these univariant numbers reported on last month were only in the 70s and 80s. Uninformed shareholders, including me, were disappointed by these numbers. We were expecting numbers in the 90s. What I didn't understand before was that we can report on each univariant biomarker independently. When we do.... we get a lesser number than when we combine all five together (multivariant). It is when we combine all of them together that we get the good high results in the 90s.
We all need to get more informed about this stuff. It can be confusing. AMBS might release numbers that horrifies shareholders, but thrills scientists! That means we're not up to speed. I am not a scientist, and I welcome more qualified science people to explain this better than I'm attempting to. But my understanding is that if you only take a reading on just one of our univariant biomarkers, the numbers are going to be much lower than what we've been accustomed to talking about on the mb. It's when you compile all of them together that we get the nice multivariant numbers that put us above our competition.
Not only will LymPro be more accurate than Amivid, but LymPro is less invasive than amivid. A big MRI-like machine is needed to detect a solution that they shoot into our veins and goes into our head. And it costs around $3,500 for the test. LymPro will cost between $1,000 and $1,500, initially. LymPro is less expensive, less invasive, and more accurate. Big Pharma doing AD clinical trials will be waiting for LymPro big time!!
Another distinction we need to make when given LymPro numbers is if they are comparing Alzheimer's patients with Healthy People, or whether they're being compared to people with other forms of dementia. The numbers are different and yet we never make these distinctions in our mb discussions.
We can't just rely on our favorite metric of spec & sens numbers in the 90s without making these important distinctions about the data being presented. The sens & spec 90s numbers is a convenient way for non-science people who are here primarily for the investment to talk about messy science stuff....but unless we want another 45% haircut in the future when Lympro data is being presented, we need to raise the level of science in our mb discussions. We need this because shareholders react after data releases in very emotional ways....fueled by message board comments from flippers with dishonest, greedy motives to profit off our ignorance.
Data is coming and we need to be prepared to understand it better!
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼